Contributed to the development of an EB Registry in India, with referrals from different parts of the country
Dr Divya Gupta
Consultant, Research in rare skin disorders
Research Area
Clinical and translational research in genodermatoses and rare skin disorders, particularly epidermolysis bullosa (EB), with related interests in the clinical phenotyping and molecular diagnosis of inherited dermatological conditions, genetic testing and interpretation, rare-disease registries, multidisciplinary care, and the evaluation of practical treatment approaches.
Research Highlights
Co-authored an Indian cohort study describing clinical and allelic heterogeneity in dystrophic EB, adding data on the range of clinical presentations and genetic findings in Indian patients.
Contributed to work describing EB simplex associated with PLEC mutations in Indian families
Participated in the evaluation of a tele-dermatology model for EB, examining its contribution to patient outreach and access to care.
Co-authored educational reviews on the principles of genetics, clinical evaluation, sequencing technologies and interpretation for dermatologists, with the aim of making genetic approaches more accessible to clinical practice.
Research Projects
2019-2024: Development of a registry for Epidermolysis Bullosa in India (Funded by EB Research Partnership, USA)
2020: Safety and efficacy of Losartan in Patients with Dystrophic Epidermolysis Bullosa (DEB): an open labelled controlled trial (Funded by Indian Association of Dermatologists, Venereologists & Leprologists)
2023: Gene expression profiling of Vitiligo vulgaris skin pre- and post-phototherapy – a pilot study (Funded by TheraCUES GeoMx DSP Grant, in collaboration with Nanostring Technologies)
2026-2028: Prevalence of auto-antibodies and their clinical correlation in epidermolysis bullosa (EB)- a cross-sectional study in an Indian cohort (Funded by Indian Association of Dermatologists, Venereologists & Leprologists)
2026-2028: A Split-Body, Open label, Randomized Controlled Trial to Evaluate the Efficacy and Cost-Effectiveness of Mepilex Border versus Velfix® -S as First-Layer Dressing in Indian Patients with Epidermolysis Bullosa (Funded by Rajiv Gandhi University of Health Sciences, Karnataka)
Highlighted Publications
Viswanath A, Gupta D, Srinivasa M, et al. Integration of a tele-dermatology model for Epidermolysis Bullosa improves patient outreach: a before and after observational study. Front Digit Health. 2026;8:1848667. Published 2026 Jun 26. doi:10.3389/fdgth.2026.1848667
Dutta A, Gupta D, Ajnabi J, Dam B, Shilpashree P and Jamora C. Spatial transcriptomic analysis of the immune landscape following NBUVB treatment of vitiligo skin. Clin Transl Immunol. 2026; 15: e70080. https://doi.org/10.1002/cti2.70080
Gupta D, Jayashankar C, Srinivas M, et al. Clinical and allelic heterogeneity in dystrophic epidermolysis bullosa- lessons from an Indian cohort. PLoS One. 2023;18(8):e0289558. Published 2023 Aug 9. doi:10.1371/journal.pone.0289558
Gupta D, Jose TG, Vishwanathan GB. Genetics for dermatologists. Part 1: Fundamental concepts of structure, function, and clinical application. Indian J Dermatol Venereol Leprol. 2025;91(5):603-614. doi:10.25259/IJDVL_243_2025
Gupta D, Jose TG, Vishwanathan GB. Genetics for dermatologists. Part 2: Clinical evaluation, sequencing technologies and interpretation. Indian J Dermatol Venereol Leprol. 2025;91(6):741-751. doi:10.25259/IJDVL_500_2024
Current Lab Members
Theory Courses Taught
Theory classes for MSc students on EB and genodermatoses
